Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 May;75(5):669–676. doi: 10.1136/jnnp.2003.028175

Applications of positron emission tomography (PET) in neurology

Y Tai 1, P Piccini 1
PMCID: PMC1763584  PMID: 15090557

Full Text

The Full Text of this article is available as a PDF (447.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisen Paul S. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep;1(5):279–284. doi: 10.1016/s1474-4422(02)00133-3. [DOI] [PubMed] [Google Scholar]
  2. Albin R. L., Minoshima S., D'Amato C. J., Frey K. A., Kuhl D. A., Sima A. A. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996 Aug;47(2):462–466. doi: 10.1212/wnl.47.2.462. [DOI] [PubMed] [Google Scholar]
  3. Alexander G. E., Crutcher M. D., DeLong M. R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res. 1990;85:119–146. [PubMed] [Google Scholar]
  4. Antonini A., Leenders K. L., Spiegel R., Meier D., Vontobel P., Weigell-Weber M., Sanchez-Pernaute R., de Yébenez J. G., Boesiger P., Weindl A. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 1996 Dec;119(Pt 6):2085–2095. doi: 10.1093/brain/119.6.2085. [DOI] [PubMed] [Google Scholar]
  5. Bachoud-Lévi A. C., Rémy P., Nguyen J. P., Brugières P., Lefaucheur J. P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet. 2000 Dec 9;356(9246):1975–1979. doi: 10.1016/s0140-6736(00)03310-9. [DOI] [PubMed] [Google Scholar]
  6. Bacskai Brian J., Klunk William E., Mathis Chester A., Hyman Bradley T. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab. 2002 Sep;22(9):1035–1041. doi: 10.1097/00004647-200209000-00001. [DOI] [PubMed] [Google Scholar]
  7. Barrington S. F. Clinical uses of PET in neurology. Nucl Med Commun. 2000 Mar;21(3):237–240. doi: 10.1097/00006231-200003000-00007. [DOI] [PubMed] [Google Scholar]
  8. Berkovic S. F., McIntosh A. M., Kalnins R. M., Jackson G. D., Fabinyi G. C., Brazenor G. A., Bladin P. F., Hopper J. L. Preoperative MRI predicts outcome of temporal lobectomy: an actuarial analysis. Neurology. 1995 Jul;45(7):1358–1363. doi: 10.1212/wnl.45.7.1358. [DOI] [PubMed] [Google Scholar]
  9. Blank S. Catrin, Bird Helen, Turkheimer Federico, Wise Richard J. S. Speech production after stroke: the role of the right pars opercularis. Ann Neurol. 2003 Sep;54(3):310–320. doi: 10.1002/ana.10656. [DOI] [PubMed] [Google Scholar]
  10. Breier A., Su T. P., Saunders R., Carson R. E., Kolachana B. S., de Bartolomeis A., Weinberger D. R., Weisenfeld N., Malhotra A. K., Eckelman W. C. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569–2574. doi: 10.1073/pnas.94.6.2569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Brock C. S., Young H., O'Reilly S. M., Matthews J., Osman S., Evans H., Newlands E. S., Price P. M. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer. 2000 Feb;82(3):608–615. doi: 10.1054/bjoc.1999.0971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Brooks D. J. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology. 1993 Dec;43(12 Suppl 6):S6–16. [PubMed] [Google Scholar]
  13. Brooks D. J., Piccini P. Non-invasive in vivo imaging of transplant function. Prog Brain Res. 2000;127:321–332. doi: 10.1016/s0079-6123(00)27015-5. [DOI] [PubMed] [Google Scholar]
  14. Brooks D. J. Positron emission tomography studies in movement disorders. Neurosurg Clin N Am. 1998 Apr;9(2):263–282. [PubMed] [Google Scholar]
  15. Brooks David J. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol. 2003;53 (Suppl 3):S110–S119. doi: 10.1002/ana.10480. [DOI] [PubMed] [Google Scholar]
  16. Burn D. J., Sawle G. V., Brooks D. J. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):278–284. doi: 10.1136/jnnp.57.3.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cagnin A., Brooks D. J., Kennedy A. M., Gunn R. N., Myers R., Turkheimer F. E., Jones T., Banati R. B. In-vivo measurement of activated microglia in dementia. Lancet. 2001 Aug 11;358(9280):461–467. doi: 10.1016/S0140-6736(01)05625-2. [DOI] [PubMed] [Google Scholar]
  18. Ceballos-Baumann A. O., Boecker H., Bartenstein P., von Falkenhayn I., Riescher H., Conrad B., Moringlane J. R., Alesch F. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol. 1999 Aug;56(8):997–1003. doi: 10.1001/archneur.56.8.997. [DOI] [PubMed] [Google Scholar]
  19. Chollet F., DiPiero V., Wise R. J., Brooks D. J., Dolan R. J., Frackowiak R. S. The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol. 1991 Jan;29(1):63–71. doi: 10.1002/ana.410290112. [DOI] [PubMed] [Google Scholar]
  20. De Witte O., Goldberg I., Wikler D., Rorive S., Damhaut P., Monclus M., Salmon I., Brotchi J., Goldman S. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001 Nov;95(5):746–750. doi: 10.3171/jns.2001.95.5.0746. [DOI] [PubMed] [Google Scholar]
  21. Dethy S., Goldman S., Blecic S., Luxen A., Levivier M., Hildebrand J. Carbon-11-methionine and fluorine-18-FDG PET study in brain hematoma. J Nucl Med. 1994 Jul;35(7):1162–1166. [PubMed] [Google Scholar]
  22. Di Chiro G., DeLaPaz R. L., Brooks R. A., Sokoloff L., Kornblith P. L., Smith B. H., Patronas N. J., Kufta C. V., Kessler R. M., Johnston G. S. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982 Dec;32(12):1323–1329. doi: 10.1212/wnl.32.12.1323. [DOI] [PubMed] [Google Scholar]
  23. Duncan J. S. Imaging and epilepsy. Brain. 1997 Feb;120(Pt 2):339–377. doi: 10.1093/brain/120.2.339. [DOI] [PubMed] [Google Scholar]
  24. Engel J., Jr, Kuhl D. E., Phelps M. E. Regional brain metabolism during seizures in humans. Adv Neurol. 1983;34:141–148. [PubMed] [Google Scholar]
  25. Feeney D. M., Baron J. C. Diaschisis. Stroke. 1986 Sep-Oct;17(5):817–830. doi: 10.1161/01.str.17.5.817. [DOI] [PubMed] [Google Scholar]
  26. Fine J., Duff J., Chen R., Chir B., Hutchison W., Lozano A. M., Lang A. E. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. N Engl J Med. 2000 Jun 8;342(23):1708–1714. doi: 10.1056/NEJM200006083422304. [DOI] [PubMed] [Google Scholar]
  27. Francavilla T. L., Miletich R. S., Di Chiro G., Patronas N. J., Rizzoli H. V., Wright D. C. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery. 1989 Jan;24(1):1–5. doi: 10.1227/00006123-198901000-00001. [DOI] [PubMed] [Google Scholar]
  28. Friston K. J., Frith C. D., Liddle P. F., Dolan R. J., Lammertsma A. A., Frackowiak R. S. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab. 1990 Jul;10(4):458–466. doi: 10.1038/jcbfm.1990.88. [DOI] [PubMed] [Google Scholar]
  29. Furlan M., Marchal G., Viader F., Derlon J. M., Baron J. C. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol. 1996 Aug;40(2):216–226. doi: 10.1002/ana.410400213. [DOI] [PubMed] [Google Scholar]
  30. Gaillard W. D., Bhatia S., Bookheimer S. Y., Fazilat S., Sato S., Theodore W. H. FDG-PET and volumetric MRI in the evaluation of patients with partial epilepsy. Neurology. 1995 Jan;45(1):123–126. doi: 10.1212/wnl.45.1.123. [DOI] [PubMed] [Google Scholar]
  31. Gee Antony D. Neuropharmacology and drug development. Br Med Bull. 2003;65:169–177. doi: 10.1093/bmb/65.1.169. [DOI] [PubMed] [Google Scholar]
  32. Gill Steven S., Patel Nikunj K., Hotton Gary R., O'Sullivan Karen, McCarter Renée, Bunnage Martin, Brooks David J., Svendsen Clive N., Heywood Peter. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003 Mar 31;9(5):589–595. doi: 10.1038/nm850. [DOI] [PubMed] [Google Scholar]
  33. Guadagno J. V., Calautti C., Baron J-C. Progress in imaging stroke: emerging clinical applications. Br Med Bull. 2003;65:145–157. doi: 10.1093/bmb/65.1.145. [DOI] [PubMed] [Google Scholar]
  34. Gunn R. N., Lammertsma A. A., Hume S. P., Cunningham V. J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997 Nov;6(4):279–287. doi: 10.1006/nimg.1997.0303. [DOI] [PubMed] [Google Scholar]
  35. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J. C., Odin P. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. 1999 Jun;122(Pt 6):1121–1132. doi: 10.1093/brain/122.6.1121. [DOI] [PubMed] [Google Scholar]
  36. Hagell Peter, Piccini Paola, Björklund Anders, Brundin Patrik, Rehncrona Stig, Widner Håkan, Crabb Lesley, Pavese Nicola, Oertel Wolfgang H., Quinn Niall. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 2002 Jul;5(7):627–628. doi: 10.1038/nn863. [DOI] [PubMed] [Google Scholar]
  37. Hammers A., Koepp M. J., Hurlemann R., Thom M., Richardson M. P., Brooks D. J., Duncan J. S. Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. Brain. 2002 Oct;125(Pt 10):2257–2271. doi: 10.1093/brain/awf233. [DOI] [PubMed] [Google Scholar]
  38. Heiss W. D., Kracht L. W., Thiel A., Grond M., Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain. 2001 Jan;124(Pt 1):20–29. doi: 10.1093/brain/124.1.20. [DOI] [PubMed] [Google Scholar]
  39. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995 Spring;9(1):6–16. doi: 10.1097/00002093-199505000-00004. [DOI] [PubMed] [Google Scholar]
  40. Hu M. T., Taylor-Robinson S. D., Chaudhuri K. R., Bell J. D., Labbé C., Cunningham V. J., Koepp M. J., Hammers A., Morris R. G., Turjanski N. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain. 2000 Feb;123(Pt 2):340–352. doi: 10.1093/brain/123.2.340. [DOI] [PubMed] [Google Scholar]
  41. Jenkins I. H., Fernandez W., Playford E. D., Lees A. J., Frackowiak R. S., Passingham R. E., Brooks D. J. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol. 1992 Dec;32(6):749–757. doi: 10.1002/ana.410320608. [DOI] [PubMed] [Google Scholar]
  42. Johnson E. W., de Lanerolle N. C., Kim J. H., Sundaresan S., Spencer D. D., Mattson R. H., Zoghbi S. S., Baldwin R. M., Hoffer P. B., Seibyl J. P. "Central" and "peripheral" benzodiazepine receptors: opposite changes in human epileptogenic tissue. Neurology. 1992 Apr;42(4):811–815. doi: 10.1212/wnl.42.4.811. [DOI] [PubMed] [Google Scholar]
  43. Koepp M. J., Gunn R. N., Lawrence A. D., Cunningham V. J., Dagher A., Jones T., Brooks D. J., Bench C. J., Grasby P. M. Evidence for striatal dopamine release during a video game. Nature. 1998 May 21;393(6682):266–268. doi: 10.1038/30498. [DOI] [PubMed] [Google Scholar]
  44. Koepp M. J., Hand K. S., Labbé C., Richardson M. P., Van Paesschen W., Baird V. H., Cunningham V. J., Bowery N. G., Brooks D. J., Duncan J. S. In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. Ann Neurol. 1998 May;43(5):618–626. doi: 10.1002/ana.410430510. [DOI] [PubMed] [Google Scholar]
  45. Kordower J. H., Freeman T. B., Snow B. J., Vingerhoets F. J., Mufson E. J., Sanberg P. R., Hauser R. A., Smith D. A., Nauert G. M., Perl D. P. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med. 1995 Apr 27;332(17):1118–1124. doi: 10.1056/NEJM199504273321702. [DOI] [PubMed] [Google Scholar]
  46. Krack Paul, Batir Alina, Van Blercom Nadège, Chabardes Stephan, Fraix Valérie, Ardouin Claire, Koudsie Adnan, Limousin Patricia Dowsey, Benazzouz Abdelhamid, LeBas Jean François. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003 Nov 13;349(20):1925–1934. doi: 10.1056/NEJMoa035275. [DOI] [PubMed] [Google Scholar]
  47. Kuzniecky R., Garcia J. H., Faught E., Morawetz R. B. Cortical dysplasia in temporal lobe epilepsy: magnetic resonance imaging correlations. Ann Neurol. 1991 Mar;29(3):293–298. doi: 10.1002/ana.410290311. [DOI] [PubMed] [Google Scholar]
  48. Lang A. E., Lozano A. M. Parkinson's disease. First of two parts. N Engl J Med. 1998 Oct 8;339(15):1044–1053. doi: 10.1056/NEJM199810083391506. [DOI] [PubMed] [Google Scholar]
  49. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000 Mar;20(3):423–451. doi: 10.1097/00004647-200003000-00001. [DOI] [PubMed] [Google Scholar]
  50. Leiderman D. B., Albert P., Balish M., Bromfield E., Theodore W. H. The dynamics of metabolic change following seizures as measured by positron emission tomography with fludeoxyglucose F 18. Arch Neurol. 1994 Sep;51(9):932–936. doi: 10.1001/archneur.1994.00540210106019. [DOI] [PubMed] [Google Scholar]
  51. Marco P., Sola R. G., Pulido P., Alijarde M. T., Sánchez A., Ramón y Cajal S., DeFelipe J. Inhibitory neurons in the human epileptogenic temporal neocortex. An immunocytochemical study. Brain. 1996 Aug;119(Pt 4):1327–1347. doi: 10.1093/brain/119.4.1327. [DOI] [PubMed] [Google Scholar]
  52. Martin W. R., Clark C., Ammann W., Stoessl A. J., Shtybel W., Hayden M. R. Cortical glucose metabolism in Huntington's disease. Neurology. 1992 Jan;42(1):223–229. doi: 10.1212/wnl.42.1.223. [DOI] [PubMed] [Google Scholar]
  53. Maziere M., Hantraye P., Prenant C., Sastre J., Comar D. Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot. 1984 Oct;35(10):973–976. doi: 10.1016/0020-708x(84)90215-1. [DOI] [PubMed] [Google Scholar]
  54. Mazziotta J. C., Frackowiak R. S., Phelps M. E. The use of positron emission tomography in the clinical assessment of dementia. Semin Nucl Med. 1992 Oct;22(4):233–246. doi: 10.1016/s0001-2998(05)80118-7. [DOI] [PubMed] [Google Scholar]
  55. Minoshima S., Foster N. L., Sima A. A., Frey K. A., Albin R. L., Kuhl D. E. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001 Sep;50(3):358–365. doi: 10.1002/ana.1133. [DOI] [PubMed] [Google Scholar]
  56. Morrish P. K., Sawle G. V., Brooks D. J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996 Apr;119(Pt 2):585–591. doi: 10.1093/brain/119.2.585. [DOI] [PubMed] [Google Scholar]
  57. Morrish P. K., Sawle G. V., Brooks D. J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 1995 Dec;59(6):597–600. doi: 10.1136/jnnp.59.6.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. O'Doherty M. J., Barrington S. F., Campbell M., Lowe J., Bradbeer C. S. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997 Oct;38(10):1575–1583. [PubMed] [Google Scholar]
  59. Ogawa T., Kanno I., Shishido F., Inugami A., Higano S., Fujita H., Murakami M., Uemura K., Yasui N., Mineura K. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 1991 May;32(3):197–202. [PubMed] [Google Scholar]
  60. Patronas N. J., Di Chiro G., Kufta C., Bairamian D., Kornblith P. L., Simon R., Larson S. M. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985 Jun;62(6):816–822. doi: 10.3171/jns.1985.62.6.0816. [DOI] [PubMed] [Google Scholar]
  61. Pavese Nicola, Andrews Thomasin C., Brooks David J., Ho Aileen K., Rosser Anne E., Barker Roger A., Robbins Trevor W., Sahakian Barbara J., Dunnett Stephen B., Piccini Paola. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain. 2003 May;126(Pt 5):1127–1135. doi: 10.1093/brain/awg119. [DOI] [PubMed] [Google Scholar]
  62. Piccini P., Brooks D. J., Björklund A., Gunn R. N., Grasby P. M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 1999 Dec;2(12):1137–1140. doi: 10.1038/16060. [DOI] [PubMed] [Google Scholar]
  63. Piccini P., Lindvall O., Björklund A., Brundin P., Hagell P., Ceravolo R., Oertel W., Quinn N., Samuel M., Rehncrona S. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000 Nov;48(5):689–695. [PubMed] [Google Scholar]
  64. Piccini Paola. Dyskinesias after transplantation in Parkinson's disease. Lancet Neurol. 2002 Dec;1(8):472–472. doi: 10.1016/s1474-4422(02)00235-1. [DOI] [PubMed] [Google Scholar]
  65. Reiman E. M., Caselli R. J., Chen K., Alexander G. E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334–3339. doi: 10.1073/pnas.061509598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Reiman E. M., Caselli R. J., Yun L. S., Chen K., Bandy D., Minoshima S., Thibodeau S. N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996 Mar 21;334(12):752–758. doi: 10.1056/NEJM199603213341202. [DOI] [PubMed] [Google Scholar]
  67. Rozental J. M., Levine R. L., Mehta M. P., Kinsella T. J., Levin A. B., Algan O., Mendoza M., Hanson J. M., Schrader D. A., Nickles R. J. Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1991 May;20(5):1053–1060. doi: 10.1016/0360-3016(91)90204-h. [DOI] [PubMed] [Google Scholar]
  68. Rozental J. M., Levine R. L., Nickles R. J., Dobkin J. A. Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol. 1989 Dec;46(12):1302–1307. doi: 10.1001/archneur.1989.00520480044018. [DOI] [PubMed] [Google Scholar]
  69. Ryvlin P., Bouvard S., Le Bars D., De Lamérie G., Grégoire M. C., Kahane P., Froment J. C., Mauguière F. Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Brain. 1998 Nov;121(Pt 11):2067–2081. doi: 10.1093/brain/121.11.2067. [DOI] [PubMed] [Google Scholar]
  70. Salmon E., Gregoire M. C., Delfiore G., Lemaire C., Degueldre C., Franck G., Comar D. Combined study of cerebral glucose metabolism and [11C]methionine accumulation in probable Alzheimer's disease using positron emission tomography. J Cereb Blood Flow Metab. 1996 May;16(3):399–408. doi: 10.1097/00004647-199605000-00006. [DOI] [PubMed] [Google Scholar]
  71. Salmon Eric. Functional brain imaging applications to differential diagnosis in the dementias. Curr Opin Neurol. 2002 Aug;15(4):439–444. doi: 10.1097/00019052-200208000-00006. [DOI] [PubMed] [Google Scholar]
  72. Samuel M., Ceballos-Baumann A. O., Turjanski N., Boecker H., Gorospe A., Linazasoro G., Holmes A. P., DeLong M. R., Vitek J. L., Thomas D. G. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study. Brain. 1997 Aug;120(Pt 8):1301–1313. doi: 10.1093/brain/120.8.1301. [DOI] [PubMed] [Google Scholar]
  73. Savic I., Ingvar M., Stone-Elander S. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry. 1993 Jun;56(6):615–621. doi: 10.1136/jnnp.56.6.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Savic I., Persson A., Roland P., Pauli S., Sedvall G., Widén L. In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet. 1988 Oct 15;2(8616):863–866. doi: 10.1016/s0140-6736(88)92468-3. [DOI] [PubMed] [Google Scholar]
  75. Silverman D. H., Small G. W., Chang C. Y., Lu C. S., Kung De Aburto M. A., Chen W., Czernin J., Rapoport S. I., Pietrini P., Alexander G. E. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001 Nov 7;286(17):2120–2127. doi: 10.1001/jama.286.17.2120. [DOI] [PubMed] [Google Scholar]
  76. Small G. W., Ercoli L. M., Silverman D. H., Huang S. C., Komo S., Bookheimer S. Y., Lavretsky H., Miller K., Siddarth P., Rasgon N. L. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6037–6042. doi: 10.1073/pnas.090106797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Small G. W., Mazziotta J. C., Collins M. T., Baxter L. R., Phelps M. E., Mandelkern M. A., Kaplan A., La Rue A., Adamson C. F., Chang L. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995 Mar 22;273(12):942–947. [PubMed] [Google Scholar]
  78. Snow B. J., Tooyama I., McGeer E. G., Yamada T., Calne D. B., Takahashi H., Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993 Sep;34(3):324–330. doi: 10.1002/ana.410340304. [DOI] [PubMed] [Google Scholar]
  79. Spinks T. J., Jones T., Bloomfield P. M., Bailey D. L., Miller M., Hogg D., Jones W. F., Vaigneur K., Reed J., Young J. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol. 2000 Sep;45(9):2601–2618. doi: 10.1088/0031-9155/45/9/313. [DOI] [PubMed] [Google Scholar]
  80. Tsuyuguchi Naohiro, Sunada Ichiro, Iwai Yoshiyasu, Yamanaka Kazuhiro, Tanaka Kiyoaki, Takami Toshihiro, Otsuka Yumiko, Sakamoto Shinichi, Ohata Kenji, Goto Takeo. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg. 2003 May;98(5):1056–1064. doi: 10.3171/jns.2003.98.5.1056. [DOI] [PubMed] [Google Scholar]
  81. Turjanski N., Weeks R., Dolan R., Harding A. E., Brooks D. J. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain. 1995 Jun;118(Pt 3):689–696. doi: 10.1093/brain/118.3.689. [DOI] [PubMed] [Google Scholar]
  82. Valk P. E., Budinger T. F., Levin V. A., Silver P., Gutin P. H., Doyle W. K. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg. 1988 Dec;69(6):830–838. doi: 10.3171/jns.1988.69.6.0830. [DOI] [PubMed] [Google Scholar]
  83. Villringer K., Jäger H., Dichgans M., Ziegler S., Poppinger J., Herz M., Kruschke C., Minoshima S., Pfister H. W., Schwaiger M. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr. 1995 Jul-Aug;19(4):532–536. doi: 10.1097/00004728-199507000-00004. [DOI] [PubMed] [Google Scholar]
  84. Weeks R. A., Piccini P., Harding A. E., Brooks D. J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 1996 Jul;40(1):49–54. doi: 10.1002/ana.410400110. [DOI] [PubMed] [Google Scholar]
  85. Whone Alan L., Moore Robert Y., Piccini Paola P., Brooks David J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol. 2003 Feb;53(2):206–213. doi: 10.1002/ana.10427. [DOI] [PubMed] [Google Scholar]
  86. Wiebe S., Blume W. T., Girvin J. P., Eliasziw M., Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001 Aug 2;345(5):311–318. doi: 10.1056/NEJM200108023450501. [DOI] [PubMed] [Google Scholar]
  87. Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A. A., Pruim J., Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999 Dec;35(13):1773–1782. doi: 10.1016/s0959-8049(99)00229-4. [DOI] [PubMed] [Google Scholar]
  88. de Leon M. J., Convit A., Wolf O. T., Tarshish C. Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A. J., Roche A. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A. 2001 Aug 28;98(19):10966–10971. doi: 10.1073/pnas.191044198. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES